- Home
- MAIA vs VTVT Comparison
MAIA vs VTVT Comparison
Compare MAIA & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- VTVT
- Stock Information
- Founded
- MAIA 2018
- VTVT 2015
- Country
- MAIA United States
- VTVT United States
- Employees
- MAIA N/A
- VTVT N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- VTVT Health Care
- Exchange
- MAIA Nasdaq
- VTVT Nasdaq
- Market Cap
- MAIA 56.7M
- VTVT 54.4M
- IPO Year
- MAIA 2022
- VTVT 2015
- Fundamental
- Price
- MAIA $1.32
- VTVT $20.61
- Analyst Decision
- MAIA
- VTVT Strong Buy
- Analyst Count
- MAIA 0
- VTVT 2
- Target Price
- MAIA N/A
- VTVT $35.50
- AVG Volume (30 Days)
- MAIA 594.6K
- VTVT 4.6K
- Earning Date
- MAIA 11-11-2025
- VTVT 11-11-2025
- Dividend Yield
- MAIA N/A
- VTVT N/A
- EPS Growth
- MAIA N/A
- VTVT N/A
- EPS
- MAIA N/A
- VTVT N/A
- Revenue
- MAIA N/A
- VTVT $17,000.00
- Revenue This Year
- MAIA N/A
- VTVT N/A
- Revenue Next Year
- MAIA N/A
- VTVT N/A
- P/E Ratio
- MAIA N/A
- VTVT N/A
- Revenue Growth
- MAIA N/A
- VTVT N/A
- 52 Week Low
- MAIA $1.27
- VTVT $12.62
- 52 Week High
- MAIA $3.48
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- MAIA 34.23
- VTVT 45.03
- Support Level
- MAIA $1.65
- VTVT $19.80
- Resistance Level
- MAIA $1.97
- VTVT $23.05
- Average True Range (ATR)
- MAIA 0.12
- VTVT 1.11
- MACD
- MAIA -0.05
- VTVT -0.50
- Stochastic Oscillator
- MAIA 4.45
- VTVT 9.23
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.